All sponsors

Hanmi Pharmaceutical Company Limited $128940.KS

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS8
PHASE 3 / 2-33
RECRUITING5
READOUTS ≤12 MONTHS5
Open Hanmi Pharmaceutical Company Limited on the live radar map → 📅 $128940.KS readout calendar (.ics)
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
HM15136
NCT04732416
P2Active, not recruitingCongenital Hyperinsulinism172026-06-16 (+42 mo)
HM15275
NCT07205900
P2Active, not recruitingObese; Obesity2672027-01
HIP2602 + HPP2602-2
NCT07899073
P3RecruitingErectile Dysfunction2252027-09
HM15275
NCT07527650
P2RecruitingType 2 Diabetes Mellitus; T2DM1802027-10
HCP1803-3
NCT07660796
P3Not yet recruitingHypertension2562027-10-30
HM11260C
NCT07379333
P3RecruitingType 2 Diabetes1182027-11
HM15912 Active
NCT04775706
P2RecruitingShort Bowel Syndrome182027-12 (+48 mo)
Belvarafenib
NCT07449754
P2RecruitingAdvanced or Metastatic Melanoma452029-09